What is Therapeuticsmd Inc's earnings per share (EPS)?

Therapeuticsmd Inc (TXMD) reported diluted earnings per share of $-0.05 for fiscal year 2025. This represents a 73.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Therapeuticsmd Inc Financials

TXMD

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Therapeuticsmd Inc (TXMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 52/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Therapeuticsmd Inc has an operating margin of -145.3%, meaning the company retains $-145 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -270.3% the prior year.

Growth

100

Therapeuticsmd Inc's revenue surged 71.6% year-over-year to $3.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Therapeuticsmd Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Therapeuticsmd Inc's current ratio of 3.02 indicates adequate short-term liquidity, earning a score of 58/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Therapeuticsmd Inc generates a -2.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 6/100. This is up from -8.0% the prior year.

Piotroski F-Score Neutral

5/9

Therapeuticsmd Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-4.31x

For every $1 of reported earnings, Therapeuticsmd Inc generates $-4.31 in operating cash flow ($2.5M OCF vs -$569K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-548.8x

Therapeuticsmd Inc earns $-548.8 in operating income for every $1 of interest expense (-$4.4M vs $8K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.0M

YoY+71.6%

5Y CAGR-45.8%

10Y CAGR-17.3%

Therapeuticsmd Inc generated $3.0M in revenue in fiscal year 2025. This represents an increase of 71.6% from the prior year.

EBITDA

-$4.0M

YoY+5.8%

Therapeuticsmd Inc's EBITDA was -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.8% from the prior year.

Net Income

-$569K

YoY+73.9%

Therapeuticsmd Inc reported -$569K in net income in fiscal year 2025. This represents an increase of 73.9% from the prior year.

EPS (Diluted)

$-0.05

YoY+73.7%

Therapeuticsmd Inc earned $-0.05 per diluted share (EPS) in fiscal year 2025. This represents an increase of 73.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.1M

YoY+0.0%

5Y CAGR-42.5%

10Y CAGR-22.5%

Therapeuticsmd Inc held $5.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

12M

YoY+0.4%

5Y CAGR-47.8%

10Y CAGR-23.9%

Therapeuticsmd Inc had 12M shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-145.3%

YoY+125.0pp

5Y CAGR+94.5pp

10Y CAGR+277.7pp

Therapeuticsmd Inc's operating margin was -145.3% in fiscal year 2025, reflecting core business profitability. This is up 125.0 percentage points from the prior year.

Net Margin

-18.8%

YoY+105.0pp

5Y CAGR+264.1pp

10Y CAGR+403.5pp

Therapeuticsmd Inc's net profit margin was -18.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 105.0 percentage points from the prior year.

Return on Equity

-2.1%

YoY+5.8pp

10Y CAGR+132.8pp

Therapeuticsmd Inc's ROE was -2.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

TXMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.0M+71.6%	$1.8M+35.3%	$1.3M-98.1%	$70.0M+2619.1%	$2.6M-96.0%	$64.9M
Cost of Revenue	N/A	N/A	N/A	$1.4M-0.4%	$1.4M-91.2%	$16.0M
Gross Profit	N/A	N/A	$1.3M-98.1%	$68.6M+5755.3%	$1.2M-97.6%	$48.9M
R&D Expenses	N/A	N/A	N/A	N/A	$7.1M-32.1%	$10.4M
SG&A Expenses	$6.9M+44.4%	$4.7M-46.7%	$8.9M-84.3%	$56.7M-29.8%	$80.7M-58.2%	$193.0M
Operating Income	-$4.4M+7.8%	-$4.8M+44.2%	-$8.5M-815.6%	$1.2M+101.5%	-$79.6M+48.8%	-$155.5M
Interest Expense	$8K-15.8%	$10K-96.8%	$300K+50.0%	$200K-99.4%	$32.9M+15.2%	$28.6M
Income Tax	-$31K0.0%	-$31K+27.9%	-$43K	N/A	N/A	N/A
Net Income	-$569K+73.9%	-$2.2M+78.8%	-$10.3M-109.2%	$112.0M+165.0%	-$172.4M+6.1%	-$183.5M
EPS (Diluted)	$-0.05+73.7%	$-0.19+80.8%	$-0.99-108.3%	$11.96+155.2%	$-21.66	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$784K-17.6%	$952K+142.2%	$393K-41.1%	$667K+21.9%	$547K+133.8%	$234K-25.2%	$313K-37.6%	$502K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$502K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.5M-2.1%	$1.6M+43.5%	$1.1M+323.9%	$255K-83.9%	$1.6M+0.2%	$1.6M+19.7%	$1.3M-10.4%	$1.5M
Operating Income	-$862K-24.0%	-$695K+20.2%	-$871K-385.6%	$305K+126.9%	-$1.1M+59.3%	-$2.8M-144.2%	-$1.1M+29.1%	-$1.6M
Interest Expense	$3K+50.0%	$2K0.0%	$2K	N/A	$3K-40.0%	$5K	N/A	$185K
Income Tax	N/A	N/A	-$32K	N/A	N/A	N/A	N/A	N/A
Net Income	$152K-72.4%	$551K+184.4%	-$653K-359.1%	$252K+141.4%	-$609K+44.1%	-$1.1M-48.5%	-$734K+16.9%	-$883K
EPS (Diluted)	$0.01-80.0%	$0.05+183.3%	$-0.06	N/A	$-0.05+44.4%	$-0.09-50.0%	$-0.06	N/A

TXMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$37.7M-3.0%	$38.8M-10.4%	$43.3M-52.1%	$90.5M-46.6%	$169.5M-6.7%	$181.6M
Current Assets	$14.4M+17.8%	$12.3M+3.9%	$11.8M-78.7%	$55.4M-53.7%	$119.5M-7.0%	$128.4M
Cash & Equivalents	$5.1M0.0%	$5.1M+16.9%	$4.3M-91.2%	$49.3M-24.0%	$64.9M-19.4%	$80.5M
Inventory	N/A	N/A	N/A	N/A	$7.6M-4.6%	$8.0M
Accounts Receivable	N/A	N/A	N/A	N/A	$36.2M+11.7%	$32.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.8M-5.9%	$11.5M-18.3%	$14.0M-74.7%	$55.3M-79.0%	$263.1M-13.9%	$305.6M
Current Liabilities	$4.8M-7.4%	$5.2M-24.6%	$6.9M-85.4%	$46.8M-81.5%	$252.9M+326.9%	$59.2M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$237.7M
Total Equity	$26.9M-1.8%	$27.4M-6.5%	$29.3M-16.7%	$35.1M+137.5%	-$93.6M+24.5%	-$124.0M
Retained Earnings	-$952.4M-0.1%	-$951.8M-0.2%	-$949.6M-1.1%	-$939.4M+10.7%	-$1.1B-19.6%	-$878.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$38.7M+0.4%	$38.5M+0.7%	$38.2M-1.5%	$38.8M	N/A	$40.1M	N/A	$43.3M
Current Assets	$14.5M+7.7%	$13.5M+7.6%	$12.5M+2.1%	$12.3M	N/A	$11.8M	N/A	$11.8M
Cash & Equivalents	$7.1M+17.2%	$6.1M+5.6%	$5.7M+13.6%	$5.1M+0.2%	$5.0M-3.5%	$5.2M+20.6%	$4.3M+0.3%	$4.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.2M+0.1%	$11.2M-2.5%	$11.5M+0.4%	$11.5M	N/A	$12.5M	N/A	$14.0M
Current Liabilities	$4.9M+6.1%	$4.7M-1.7%	$4.7M-8.2%	$5.2M	N/A	$5.8M	N/A	$6.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$27.4M+0.6%	$27.3M+2.1%	$26.7M-2.3%	$27.4M+1.0%	$27.1M-2.1%	$27.7M-3.5%	$28.7M-2.1%	$29.3M
Retained Earnings	-$951.8M0.0%	-$951.9M+0.1%	-$952.5M-0.1%	-$951.8M	N/A	-$951.5M	N/A	-$949.6M

TXMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$2.5M+109.7%	$1.2M+105.1%	-$23.1M-346.6%	$9.4M+106.6%	-$142.7M+10.5%	-$159.5M
Capital Expenditures	N/A	N/A	N/A	N/A	$34K-83.6%	$207K
Free Cash Flow	N/A	N/A	N/A	N/A	-$142.7M+10.6%	-$159.7M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$2.2M-39.1%	-$1.6M
Financing Cash Flow	N/A	N/A	$3.2M	N/A	$129.6M+60.5%	$80.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$999K+162.2%	$381K-45.5%	$699K+4011.8%	$17K+123.9%	-$71K-104.9%	$1.5M+734.5%	-$229K+95.4%	-$5.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TXMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	100.0%+2.0pp	98.0%+52.5pp	45.5%-29.9pp	75.4%
Operating Margin	-145.3%+125.0pp	-270.3%+384.3pp	-654.6%-656.3pp	1.7%+3094.5pp	-3092.8%-2853.0pp	-239.8%
Net Margin	-18.8%+105.0pp	-123.8%+665.5pp	-789.4%-949.5pp	160.1%+6861.0pp	-6700.9%-6418.0pp	-282.9%
Return on Equity	-2.1%+5.8pp	-8.0%+27.1pp	-35.1%-353.8pp	318.7%	N/A	N/A
Return on Assets	-1.5%+4.1pp	-5.6%+18.1pp	-23.7%-147.5pp	123.8%+225.6pp	-101.7%-0.7pp	-101.0%
Current Ratio	3.02+0.6	2.37+0.7	1.72+0.5	1.18+0.7	0.47-1.7	2.17
Debt-to-Equity	0.40-0.0	0.42-0.1	0.48-1.1	1.57+1.6	0.00+1.9	-1.92
FCF Margin	N/A	N/A	N/A	N/A	-5547.1%-5301.0pp	-246.1%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%
Operating Margin	-109.9%-36.9pp	-73.0%+148.6pp	-221.6%-267.4pp	45.7%+253.0pp	-207.3%+984.6pp	-1191.9%-827.0pp	-364.9%-43.9pp	-320.9%
Net Margin	19.4%-38.5pp	57.9%+224.0pp	-166.2%-203.9pp	37.8%+149.1pp	-111.3%+354.5pp	-465.8%-231.3pp	-234.5%-58.6pp	-175.9%
Return on Equity	0.5%-1.5pp	2.0%+4.5pp	-2.4%-3.4pp	0.9%+3.2pp	-2.3%+1.7pp	-3.9%-1.4pp	-2.6%+0.5pp	-3.0%
Return on Assets	0.4%-1.0pp	1.4%+3.1pp	-1.7%-2.4pp	0.7%	N/A	-2.7%	N/A	-2.0%
Current Ratio	2.93+0.0	2.89+0.2	2.64+0.3	2.37	N/A	2.03	N/A	1.72
Debt-to-Equity	0.410.0	0.41-0.0	0.43+0.0	0.42	N/A	0.45	N/A	0.48
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Flora Growth Corp FLGC

$21.6M

Gelteq Limited GELS

$7.3M

Im Cannabis Corp IMCC

$2.0M

Biofrontera Inc BFRI

$11.4M

Aytu Biopharma Inc AYTU

$28.8M

Frequently Asked Questions

What is Therapeuticsmd Inc's annual revenue?

Therapeuticsmd Inc (TXMD) reported $3.0M in total revenue for fiscal year 2025. This represents a 71.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Therapeuticsmd Inc's revenue growing?

Therapeuticsmd Inc (TXMD) revenue grew by 71.6% year-over-year, from $1.8M to $3.0M in fiscal year 2025.

Is Therapeuticsmd Inc profitable?

No, Therapeuticsmd Inc (TXMD) reported a net income of -$569K in fiscal year 2025, with a net profit margin of -18.8%.

What is Therapeuticsmd Inc's EBITDA?

Therapeuticsmd Inc (TXMD) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Therapeuticsmd Inc's operating margin?

Therapeuticsmd Inc (TXMD) had an operating margin of -145.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Therapeuticsmd Inc's net profit margin?

Therapeuticsmd Inc (TXMD) had a net profit margin of -18.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Therapeuticsmd Inc's return on equity (ROE)?

Therapeuticsmd Inc (TXMD) has a return on equity of -2.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Therapeuticsmd Inc's operating cash flow?

Therapeuticsmd Inc (TXMD) generated $2.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Therapeuticsmd Inc's total assets?

Therapeuticsmd Inc (TXMD) had $37.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Therapeuticsmd Inc have outstanding?

Therapeuticsmd Inc (TXMD) had 12M shares outstanding as of fiscal year 2025.

What is Therapeuticsmd Inc's current ratio?

Therapeuticsmd Inc (TXMD) had a current ratio of 3.02 as of fiscal year 2025, which is generally considered healthy.

What is Therapeuticsmd Inc's debt-to-equity ratio?

Therapeuticsmd Inc (TXMD) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Therapeuticsmd Inc's return on assets (ROA)?

Therapeuticsmd Inc (TXMD) had a return on assets of -1.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Therapeuticsmd Inc's Piotroski F-Score?

Therapeuticsmd Inc (TXMD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Therapeuticsmd Inc's earnings high quality?

Therapeuticsmd Inc (TXMD) has an earnings quality ratio of -4.31x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Therapeuticsmd Inc cover its interest payments?

Therapeuticsmd Inc (TXMD) has an interest coverage ratio of -548.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Therapeuticsmd Inc?

Therapeuticsmd Inc (TXMD) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.